Search
Search Results
-
-
-
A Framework for the Administration of Anti-amyloid Monoclonal Antibody Treatments in Early-Stage Alzheimer’s Disease
The US Food and Drug Administration (FDA) approval of lecanemab for early-stage Alzheimer’s disease (AD) represents an exciting new chapter in the...
-
Kausale Alzheimertherapie
Around 130,000 Austrians suffer from dementia, predominantly Alzheimer’s disease (AD), which is projected to double by 2050. An additional...
-
Comparative Efficacy and Safety of Monoclonal Antibodies for Cognitive Decline in Patients with Alzheimer’s Disease: A Systematic Review and Network Meta-Analysis
BackgroundRecent clinical trials of anti-Aβ monoclonal antibodies (mAbs) in the treatment of early Alzheimer’s disease (AD) have produced encouraging...
-
Anti-amyloid Antibody Therapies for Alzheimer’s Disease
Alzheimer’s disease (AD) is the most common cause of dementia, which is characterized by a progressive neurodegenerative disorder that is extremely...
-
Immunotherapies Targeting Amyloid and Tau Protein in Alzheimer’s Disease: Should We Move Away from Diseases and Focus on Biological Targets? A Systematic Review and Expert Opinion
IntroductionAlzheimer’s disease (AD) is the most common cause of dementia worldwide, making it a major public health issue. Anti-amyloid and anti-tau...
-
Clarity on the blazing trail: clearing the way for amyloid-removing therapies for Alzheimer’s disease
Alzheimer’s disease (AD) is a progressive neurodegenerative disorder with a complex pathogenesis. Senile plaques composed of the amyloid-β (Aβ)...
-
The FDA-approved anti-amyloid-β monoclonal antibodies for the treatment of Alzheimer’s disease: a systematic review and meta-analysis of randomized controlled trials
BackgroundAlzheimer’s disease (AD) is a worldwide public health problem and is difficult to cure. Drugs aimed at slowing the progression of the...
-
Anti-Amyloid Monoclonal Antibodies are Transformative Treatments that Redefine Alzheimer's Disease Therapeutics
Two anti-amyloid monoclonal antibodies (MABs)—lecanemab (Leqembi ® ) and aducanumab (Aduhelm ® )—have been approved in the USA for the treatment of...
-
Real-word application of the AT(N) classification and disease-modifying treatment eligibility in a hospital-based cohort
Background and objectivesThe AT(N) classification system stratifies patients based on biomarker profiles, including amyloid-beta deposition (A), tau...
-
The Future of AD Clinical Trials with the Advent of Anti-Amyloid Therapies: An CTAD Task Force Report
BACKGROUND: Aducanumab (ADUHELM™) was approved for the treatment of Alzheimer’s disease (AD) in the US. This approval was supported by an effect on...
-
Design of a Non-Interventional Study to Assess Neurologists’ Perspectives and Pharmacological Treatment Decisions in Early Alzheimer's Disease
IntroductionThe current therapeutic landscape of Alzheimer's disease (AD) is evolving rapidly. Our treatment options include new anti-amyloid-β...
-
Kausale Therapie der Alzheimer-Krankheit: Amyloidantikörper
BackgroundAlzheimerʼs disease (AD) is the most common cause of dementia. The number of people affected will increase dramatically in the coming...
-
Alzheimer’s disease and drug delivery across the blood–brain barrier: approaches and challenges
Alzheimer's disease (AD) is a diverse disease with a complex pathophysiology. The presence of extracellular β-amyloid deposition as neuritic plaques...
